This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–46.
Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018;164(Suppl 1):S112–S118.
Bikdeli B, Jimenez D, Hawkins M, Ortíz S, Prandoni P, Brenner B, et al. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost. 2018;118(01):214–24.
Zugazagoitia J, Biosca M, Oliveira J, Olmedo ME, Dómine M, Nadal E, et al. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer. Eur Respir J. 2018;51(5):1702431.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study. Arch Intern Med. 2000;160(6):809–15.
Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy. A large retrospective analysis. J Clin Oncol. 2011;29:3466–73.
Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandalà M, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011;9:179.
Carmona-Bayonas A, Jimenez-Fonseca P, Garrido M, Custodio A, Hernandez R, Lacalle A, et al. Multistate models: accurate and dynamic methods to improve predictions of thrombotic risk in patients with cancer. Thromb Haemost. 2019 (Epub ahead of print)
Muñoz Martín AJ, Ortega I, Font C, Pachón V, Castellón V, Martínez-Marín V, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018;118:1056–61.
The authors want to express their gratitude to: (1) Sanofi for supporting TESEO registry with an unrestricted educational grant, (2) Cancer & Thrombosis Section, Spanish Society of Medical Oncology (SEOM) for promoting this registry and (3) all the researchers and centers for their inclusion of cases.
Conflict of interest
AJMM declares consulting or advisory role: Celgene, Sanofi, Pfizer, Bristol-Myers Squibb, LEO Pharma, Daiichi Sankyo, Bayer, Halozyme; speakers’ bureau: Rovi; research funding: Sanofi, LEO Pharma and patents, royalties, other intellectual property: risk assessment model in venous thromboembolism in patients with cancer. PJF has participated as speaker in meetings sponsored by Leo Pharma and Rovi, all without the scope of this project. ACB has participated as a speaker in meetings sponsored by Rovi and Leo Pharma, all without the scope of this project. EMC declares consulting or advisory role: Pfizer; speakers’ bureau: Celgene, Rovi, Leo Pharma, Roche, Sanofi, Shire. JML: no conflict of interest. PPS declares consulting or advisory role: Leo Pharma. ARL declares no conflict of interest. RVG declares consulting or advisory role: Roche Amgen, Merck and Sanofi.
The study has been performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. This study is an observational, non-interventionist trial.
Signed informed consent was obtained from all patients.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Muñoz Martín, A.J., Jiménez-Fonseca, P., Carmona-Bayonas, A. et al. TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol 22, 1423–1424 (2020). https://doi.org/10.1007/s12094-019-02265-x
- Real world evidence